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Abstract
Introduction: Amyloid β (Aβ) accumulates in the extracellular space as diffuse and neuritic plaques in Alzheimer’s
disease (AD). Aβ also deposits on the walls of arterioles as cerebral amyloid angiopathy (CAA) in most cases of AD and
sometimes independently of AD. Apolipoprotein E (apoE) ɛ4 is associated with increases in both Aβ plaques and CAA
in humans. Studies in mouse models that develop Aβ deposition have shown that murine apoE and human apoE4
have different abilities to facilitate plaque or CAA formation when studied independently. To better understand and
compare the effects of murine apoE and human apoE4, we bred 5XFAD (line 7031) transgenic mice so that they
expressed one copy of murine apoE and one copy of human apoE4 under the control of the normal murine apoE
regulatory elements (5XFAD/apoEm/4).
Results: The 5XFAD/apoEm/4 mice contained levels of parenchymal CAA that were intermediate between 5XFAD/
apoEm/m and 5XFAD/apoE4/4 mice. In 5XFAD/apoEm/4 mice, we found that Aβ parenchymal plaques co-localized with
much more apoE than did parenchymal CAA, suggesting differential co-aggregation of apoE with Aβ in plaques versus
CAA. More importantly, within the brain parenchyma of the 5XFAD/apoEm/4 mice, plaques contained more murine
apoE, which on its own results in more pronounced and earlier plaque formation, while CAA contained more human
apoE4 which on its own results in more pronounced CAA formation. We further confirmed the co-aggregation
of mouse apoE with Aβ in plaques by showing a strong correlation between insoluble mouse apoE and
insoluble Aβ in PS1APP-21/apoEm/4 mice which develop plaques without CAA.
Conclusions: These studies suggest that both murine apoE and human apoE4 facilitate differential opposing effects
in influencing Aβ plaques versus CAA via different co-aggregation with these two amyloid lesions and set the stage for
understanding these effects at a molecular level.
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Introduction
The accumulation of amyloid β (Aβ) into plaques is one
of the pathological hallmarks of Alzheimer’s disease
(AD) [13]. The vast majority of patients diagnosed with
AD also have cerebral amyloid angiopathy (CAA), de-
position of Aβ on the cerebral vessels [16]. Some
individuals develop CAA in the absence of AD [3]. CAA
often associates with hemorrhagic lesions, ischemic le-
sions, encephalopathy, and dementia [39].
The strongest known genetic risk factor for late onset
AD is the ε4 allele of apolipoprotein E (apoE), while the
ε2 allele is protective [7, 8, 33]. Human apoE4 carriers
have higher amyloid plaque load as well as greater
amounts of CAA [12, 20, 29]. ApoE influences deposition
of Aβ in plaques and CAA likely through some common
mechanisms affecting Aβ clearance and aggregation. For
example, apoE4 slows down Aβ clearance and leads to
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higher Aβ concentration [6]. This could further increase
Aβ accumulation in both plaques and CAA. ApoE co-
localizes with both amyloid plaques and CAA [21, 35, 37],
and blocking apoE/Aβ binding with a non-fibrillogenic
synthetic peptide Aβ12-28p reduces plaque load as well
as CAA [27, 40]. In addition, amyloid precursor pro-
tein (APP) transgenic mice lacking apoE have a marked
reduction of fibrillar Aβ deposition and no CAA, sug-
gesting that apoE facilitates Aβ deposition in both le-
sions [2, 11, 15].
Out of 299 amino acids, human apoE4 shares only
70 % homology with mouse apoE. Using APP transgenic
(Tg) mice that develop Aβ deposition, it has been shown
that mouse apoE is overall more amyloidogenic than any
of the human apoE isoforms [9]. In addition, mouse apoE
appears to be more prone to lead to parenchymal plaque
formation while human apoE4 is more prone to lead to
CAA formation in mice that generate wild type human
Aβ peptide [10, 24]. This conflicting pattern suggests that
apoE may affect plaques and CAA deposition via a differ-
ent mechanism(s). This difference is not likely caused by
differential overall Aβ clearance rates since a change in Aβ
clearance and consequent concentration would probably
have the same impact on both plaques and CAA. Another
possibility is that this difference is mediated by differential
co-aggregation of apoE with Aβ in parenchymal plaques
or CAA. In this study, we asked whether mouse apoE vs
human apoE4 differentially 1) lead to either parenchymal
plaque formation versus CAA and 2) co-aggregate with
Aβ in plaques and CAA by quantifying their degree of
co-localization with plaques and CAA when they are
expressed in the same brain at the same level.
Here we utilized APP Tg mice carrying one copy of
endogenous mouse apoE and one copy of apoE4 (APP/
apoEm/4). In this model, different apoE proteins interact
with Aβ under an identical in vivo microenvironment.
Therefore, the interactions between apoE and Aβ will
depend on the intrinsic properties to each apoE isoform.
We first quantified the amyloid plaque and CAA load
in 8-10 month old 5XFAD/apoEm/m, 5XFAD/apoEm/4 and
5XFAD/apoE4/4 mice and verified that apoE4 strongly
facilitated amyloid deposition in CAA, and that mouse
apoE facilitated parenchymal plaque deposition. We then
assessed 5XFAD/apoEm/4 mice and found that in the pres-
ence of both mouse apoE and human apoE4, there was an
intermediate level of CAA as compared to either 5XFAD/
apoEm/m or 5XFAD/apoE4/4 mice. In 5XFAD/apoEm/4
mice, mouse apoE co-localized with parenchymal plaques
to a significantly greater extent while apoE4 co-localized
with CAA to a significantly greater extent. Further, in
85 day old APPPS1-21/apoEm/4 mice, which have plaques
without CAA, insoluble Aβ was strongly correlated with
insoluble mouse apoE but not apoE4. The data suggest that
the type of apoE dictates whether apoE will lead to greater
plaque versus CAA and that differences in apoE sequence
and co-aggregation with plaques versus CAA likely leads
to this difference. Understanding the molecular basis for
this difference will lead to insights into disease pathogen-
esis that may have future treatment implications.
Materials and methods
Animals
5XFAD mice, line Tg7031 on a C57/B6XSJL background
(gift from Dr. Robert Vassar at Northwestern University)
co-express the KM670/671NL, I716V, and V717I muta-
tions in human APP (695), as well as the M146L and
L286V mutations in human PS1 under control of the
mouse Thy1 promoter [23]. APPPS1-21 mice on a C57BL/
6 J background (gift from Dr. Mathias Jucker at Hertie-
Institute for Clinical Brain Research) co-express human
APP with a Swedish mutation (KM670/671NL) and mu-
tant PS1 with the L166P mutation under the control of a
Thy1 promoter [25]. ApoE4 knockin mice express apoE ε4
under control of the endogenous mouse regulatory ele-
ments on a C57BL/6 J background (apoE4/4) [34]. 5XFAD
mice carrying one copy (5XFAD/apoEm/4) or two copies
(5XFAD/apoE4/4) of apoE4 were generated by breeding
5XFAD/apoEm/m with apoE4/4 mice. APPPS1-21/apoEm/4
mice were generated by breeding APPPS1-21/apoEm/m
with apoE4/4 mice. Age-matched non-APP/apoEm/4 mice
were littermates of the corresponding APP mice. All ex-
perimental protocols were approved by the Animal Studies
Committee at Washington University.
Tissue harvesting
The mice were perfused with ice cold PBS containing
0.3 % heparin. One hemibrain was dissected and flash-
frozen on dry ice and then stored at -80 °C for biochemical
assays. The other hemibrain was fixed in 4 % paraformal-
dehyde for histological study. Before staining, serial coronal
sections at 50 μm thickness were collected using a freezing
sliding microtome (Leica).
X-34 staining
Quantitative analysis of fibrillar amyloid deposition was
performed on 8-10 month old 5XFAD/apoEm/m, 5XFAD/
apoEm/4 and 5XFAD/apoE4/4 mice as previously described
[18]. Briefly, three sections per mouse (Bregma, -1.4 mm
caudal to Bregma, -2.0 mm caudal to Bregma) were
stained with X-34 and then scanned using a Nanozoomer
slide scanner (Hamamatsu Photonics). Images were exported
with NDP viewer (Hamamatsu Photonics), converted to
grayscale, thresholded to highlight positive staining of pla-
ques or CAA, and analyzed using ImageJ (National Institutes
of Health). The average area covered by X-34 from the
3 sections/mouse was used to represent each mouse.
The quantification was performed by an investigator
who was blinded for the genotype of the animals.
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Immunohistochemistry
Brain sections from 10-month-old 5XFAD/apoEm/4 or
85-day-old APPPS1-21/apoEm/4 mice were co-stained
for fibrillar amyloid, mouse apoE, and apoE4 using X-34,
anti-mouse apoE monoclonal antibody HJ6.3-Alexa Fluor
568 (generated in-house) and anti-human apoE monoclo-
nal antibody HJ15.7-Alexa Fluor 488 (generated in-house),
respectively. For quantification of apoE/CAA or apoE/
plaque co-staining in 10-month-old 5XFAD/apoEm/4 mice,
brain sections were imaged using a Zeiss LSM 5 PASCAL
system coupled to a Zeiss Axiovert 200 M confocal micro-
scope. Three sections from each mouse were used and five
fields containing CAA and five fields containing plaques
on each section were imaged. Images were thresholded for
corresponding colors and the degree of co-localization was
analyzed with ImageJ. Percent area of CAA or plaque cov-
ered by mouse apoE or apoE4 was calculated and the aver-
age from the 3 sections/mouse was used to represent each
mouse. For quantification of apoE/plaques in 85-day-old
APPPS1-21/apoEm/4 mice, which were at the initiation of
plaque deposition, all the plaques in the cortical area were
counted under Nikon Eclipse 80i fluorescent microscope
and the apoE co-staining status for each individual X-34
plaque was recorded. The average of 3 sections from each
mouse was used to represent each mouse.
Tissue lysate ELISA
Brain cortices from 85-day-old APPPS1-21/apoEm/4 and
apoEm/4 mice were sequentially homogenized with cold
PBS, 1 % triton-X 100, and 5 M guanidine buffer in the
presence of 1X protease inhibitor mixture (Roche). Aβ40,
Aβ42, mouse apoE, and apoE4 in each fraction were mea-
sured by ELISA. For Aβ40 or Aβ42 ELISA, anti-Aβ35-40
HJ2 (generated in-house) or anti-Aβ37-42 HJ7.4 (generated
in-house) was used as the capture antibody, and anti-
Aβ13-28 HJ5.1-biotin (generated in-house) as the detecting
antibody [4]. For mouse apoE ELISA, plates were coated
with HJ6.2 (in-house generated) at a concentration of
10 μg/ml in carbonate coating buffer at 4 °C overnight.
After blocking with 2 % BSA in PBS at 37 °C for 1 h,
the samples were loaded on the plates and incubated
overnight at 4 °C. Then the plates were incubated in
300 ng/ml HJ6.8-biotin (generated in-house) at 37 °C for
1.5 h. Followed by a incubation in 1:10000 Streptavidin
Poly-HRP40 Conjugate (Fitzgerald) at room temperature
for 1.5 h, the plates were developed using Super Slow
ELISA TMB (Sigma) and read on a Bio-Tek Synergy 2
plate reader at 650 nm. The standard curve was mouse
apoE purified from mouse astrocytes conditioned medium
using a polyclonal antibody (Calbiochem). Human apoE
ELISA shared the same protocol as mouse apoE ELISA
except for the antibodies were different. For human apoE
ELISA, HJ15.6 (generated in-house) at a concentration of
10 μg/ml was used as the capture antibody and 150 ng/ml
HJ15.4-biotin (generated in-house) was used as detecting
antibody. Recombinant apoE4 (Leinco) was used as the
standard for human apoE ELISA.
Data analysis
Statistical analyses were performed using GraphPad Prism
(GraphPad Software, version 5.0). All data were analyzed
using ANOVA, One-way ANOVA with repeated measures,
student t-test or paired t- test as indicated in the respect-
ive figure legends. Sample sizes were specified in the re-
spective figure legends. Data were expressed as mean ±
S.E.M. unless otherwise specified.
Results
ApoE4 shifts parenchymal Aβ deposition from plaques to
CAA in the 5XFAD mice
Plaque deposition begins in 5XFAD (line 7031) on mouse
apoE background (5XFAD/apoEm/m) at the age of 4 months.
When 5XFAD mice were bred onto an apoE4 background
(5XFAD/apoE4/4), plaque deposition began at the age of
5 months (Additional file 1: Figure S1). To further deter-
mine the effect of replacing mouse apoE with apoE4 on Aβ
plaques and CAA, we stained fibrillar amyloid with X-34 in
8-10 month old 5XFAD/apoEm/m, 5XFAD/apoEm/4 and
5XFAD/apoE4/4 mice (Fig. 1a). The amount of CAA on the
blood vessels within the brain parenchyma (parenchymal
CAA) and amyloid plaques were quantified. There is
minimal parenchymal CAA compared to amyloid pla-
ques in 5XFAD/apoEm/m animals (Fig. 1b, c). With the
introduction of one copy of apoE4 (5XFAD/apoEm/4),
the plaque load did not change while the CAA tended
to increase (Fig. 1b, c). With two copies of apoE4 (5XFAD/
apoE4/4), there was a significant reduction of plaque load
(Fig. 1b) and a significant elevation of CAA (Fig. 1c) as
compared to 5XFAD/apoEm/m mice.
Plaques contain more mouse apoE while parenchymal
CAA contain more apoE4 in 5XFAD/apoEm/4 mice
To determine whether the mouse apoE and apoE4 fa-
cilitate plaque or CAA differently via differential co-
aggregation with Aβ in plaques and CAA, we examined
the amount of apoE4 or mouse apoE co-localized with
plaques and CAA. We co-stained amyloid deposition with
an anti-mouse apoE specific antibody HJ6.3 (Additional
file 2: Figure S2) and an anti-human apoE specific anti-
body HJ15.7 (Additional file 2: Figure S2) in 10-month-old
5XFAD/apoEm/4 brains (Fig. 2). We first quantified co-
localization of each form of apoE in relation to plaques
and CAA. Within brain parenchyma, both apoE4 (3.33 ±
1.04 % in CAA vs 7.49 ± 0.71 % in plaques, n = 9, p < 0.05,
paired t-test) and mouse apoE (1.23 ± 0.63 % in CAA vs
19.89 ± 1.30 % in plaques, n = 9, p < 0.001, paired t-test)
exhibited less co-localization in parenchymal CAA as
compared to plaques. However, the amount of each form
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of apoE localized in the same lesion was different. Par-
enchymal plaques contained more mouse apoE immu-
noreactivity than apoE4 (Fig. 2a, b), whereas parenchymal
CAA contained more apoE4 immunoreactivity than mouse
apoE (Fig. 2c, d).
Next, we compared the co-localization of different
apoE within parenchymal CAA (Fig. 2c) and the CAA
on leptomeningeal vessels (leptomeningeal CAA, Fig. 3a).
Interestingly, both mouse apoE (Fig. 3c) and apoE4
(Fig. 3d) exhibited significantly more co-localization with
leptomeningeal CAA as compared to parenchymal CAA.
In addition, while apoE4 co-localized more than mouse
apoE within parenchymal CAA (Fig. 2d), leptomeningeal
CAA co-localized with less apoE4 as compared to mouse
apoE (Fig. 3b). For the mouse apoE to human apoE4
ratio, the ratios were similar in plaques and leptomen-
ingeal CAA while parenchymal CAA had the lowest
ratio (Additional file 3: Figure S3).
Mouse apoE and Aβ levels are highly correlated in
plaques in APPPS1-21/apoEm/4 cortices
To verify the differential co-aggregation of mouse vs.
human apoE4 with Aβ plaques, we utilized another
APP Tg mouse model, APPPS1-21. We first co-stained
amyloid deposition with specific anti-mouse apoE anti-
body HJ6.3 and specific anti-human apoE antibody
HJ15.7 in 85-day-old APPPS1-21/apoEm/4 mice (Fig. 4).
We found that CAA was absent in the APPPS1-21/apoEm/4
cortex at this age, probably due to the low Aβ40/Aβ42 ratio
in the APPPS1-21 mouse model [25]. Interestingly, all
(100 %) of the plaques contained mouse apoE (Fig. 4a, b);
whereas only a very small percentage (1.67 ± 1.14 %) of
plaques also contained apoE4 (Fig. 4a). There was no
plaque that only contained apoE4.
To assess the level of mouse and human apoE in cor-
tical tissue lysates of the same APPPS1-21/apoEm/4
mice, we developed both a mouse and a human apoE
Fig. 1 ApoE4 shifted parenchymal Aβ deposition from plaques to parenchymal CAA in the 5XFAD mice. 8 ~ 10 months old 5XFAD/apoEm/m,
5XFAD/apoEm/4 and 5XFAD/apoE4/4 mice were stained with X-34. a Representative brain sections with CAA (empty arrows) and plaques (solid arrows).
Scale bar, 1 mm. The right panel is the high power magnification of the area labeled in the squares in the corresponding left-side images. b The % area
covered by parenchymal fibrillar plaques in the cortex. c The % area covered by parenchymal CAA quantified in the cortex (n = 3-9/group; *p < 0.05,
One-way ANOVA followed by Tukey post-test)
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specific ELISA (Additional file 4: Figure S4). We then
performed a 3-step sequential extraction of APPPS1-
21/apoEm/4 cortex using PBS, 1 % Triton X-100 and
5 M guanidine, and measured apoE levels in these three
fractions. Tissue from age-matched non-APP transgenic
apoEm/4 mice were also analyzed as controls to see the
basal levels of apoE in the absence of amyloid plaques. In
the non-APP transgenic, apoEm/4 mice, we found that the
mouse apoE and apoE4 levels were similar in the sum of
the three fractions (Fig. 5a). However, the fractional dis-
tributions of different apoE were very different. For
mouse apoE, 50.9 ± 1.1 % was present in the PBS soluble
fraction and only 4.7 ± 0.4 % was present in the insoluble
(guanidine) fraction (Fig. 5b). ApoE4 was more equally
distributed in 3 fractions (Fig. 5b). The PBS soluble
fraction contained significantly more (p < 0.001) mouse
apoE than apoE4 (Fig. 5a), while the insoluble fraction
contained significantly more (p < 0.001) apoE4 than mouse
apoE (Fig. 5a).
In APPPS1-21/apoEm/4 cortex which contained amyloid
plaques, apoE4 absolute levels (Fig. 5c) or fractional distri-
bution (Fig. 5d) were unaltered as compared to that in
apoEm/4 cortices. For mouse apoE, the absolute levels
were unaltered in the PBS and 1 % Triton fraction of
APPPS1-21/apoEm/4 cortices as compared to that in
apoEm/4. However, the mouse apoE in the insoluble frac-
tion of APPPS1-21/apoEm/4 mice was significantly higher
than that in apoEm/4 mice (117.3 ± 21.7 vs 48.8 ± 4.4 ng/
100 mg tissue for APPPS1-21/apoEm/4 and apoEm/4,
respectively; p < 0.01, Student t-test). As a result, the
percentage of insoluble mouse apoE was increased in
APPPS1-21/apoEm/4 mice as compared to that in apoEm/4
mice (10.0 ± 1.6 % vs 4.7 ± 0.4 % for APPPS1-21/apoEm/4
and apoEm/4, respectively; p < 0.01, Student t-test; Fig. 5b, d).
The increase of insoluble mouse apoE is very likely due
to co-aggregation of mouse apoE with Aβ in the plaques,
which did not occur to a significant extent with apoE4. To
verify this possibility, we performed correlation analysis of
Fig. 2 Co-localization of mouse apoE and apoE4 in CAA or plaques within the same brain parenchyma in 5XFAD/apoEm/4 mice. 10-month-old
5XFAD/apoEm/4 mice were co-stained with HJ6.3-Alexa 568 for mouse apoE, HJ15.7-Alexa 488 for apoE4, and X-34 for fibrillar amyloid. a-b Representative
images of co-staining for mouse apoE and apoE4 in the plaques and % area of plaque covered by different apoE. c-d Representative images
of co-staining for mouse apoE and apoE4 in parenchymal CAA and % area of parenchymal CAA covered by different apoE. Values connected
by lines were measured from the same animals (n = 9/group; *p < 0.05, ***p < 0.001, paired t-test)
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Fig. 3 Comparison between apoE co-localization in parenchymal and leptomeningeal CAA in the same 5XFAD/apoEm/4 brains. Brain sections
from 10 months old 5XFAD/apoEm/4 animals were co-stained with HJ6.3-Alexa 568 for mouse apoE, HJ15.7-Alexa 488 for human apoE4, and X-34
for fibrillar amyloid. a-b Representative images of co-staining for mouse apoE and apoE4 in the leptomeningeal CAA and % area of leptomeningeal
CAA covered by different apoE (n = 9/group). Scale bars, 50 μm. c % area of plaque, parenchymal and leptomeningeal CAA covered by mouse
apoE. d % area of plaque, parenchymal and leptomeningeal CAA covered by human apoE4. Values connected by lines were measured from
the same animals (n = 8/group; **p < 0.01, ***p < 0.001, One-way ANOVA repeated measures)
Fig. 4 Co-localization of mouse apoE and apoE4 in plaques within the same brain parenchyma in APPPS1-21/apoEm/4 mice. Brain sections from
85-day-old APPPS1-21/apoEm/4 animals (n = 7) were co-stained with HJ6.3-Alexa 568 for mouse apoE, HJ15.7-Alexa 488 for human apoE4, and
X-34 for fibrillar amyloid. a Representative images and the % of plaques containing both mouse apoE and apoE4 (scale bar, 20 μm). b Representative
images and the % of plaques containing only mouse apoE (scale bar, 20 μm)
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insoluble Aβ and apoE levels in the same sample in the
cortices of these APPPS1-21/apoEm/4 mice. Mouse apoE
demonstrated a strong correlation with insoluble Aβ42
(Fig. 5e), in agreement with the observation that mouse
apoE highly co-localized with plaques by co-staining. In
contrast, apoE4, which is poorly co-localized with plaques,
demonstrated no correlation with Aβ42 (Fig. 5f). As ex-
pected, insoluble Aβ40 strongly correlated with insoluble
Aβ42 in APPPS1-21/apoE
m/4 mice (Fig. 5 g).
Discussion
APOE genotype is the strongest genetic risk factor for
late-onset AD and CAA. ApoE4 is associated with in-
creases in both plaque burden and CAA in humans relative
to the other human apoE isoforms [17]. ApoE likely influ-
ences deposition of Aβ in plaques and CAA through some
common mechanisms affecting Aβ clearance and aggrega-
tion. Interestingly, previous studies in mouse models of
amyloid deposition have shown that murine apoE is signifi-
cantly more amyloidogenic than human apoE isoforms, in-
cluding apoE4 [9, 41]. Despite the fact that it is more
amyloidogenic, previous studies showed that apoE4 led to
greater CAA than mouse apoE. In the current study, we
showed that mouse apoE and human apoE4 were each
dominant when present in the same brain (Fig. 1): mouse
apoE promoted plaques while apoE4 promoted CAA.
Overall, these findings suggest that differences in the in-
herent properties/structures of each form interact with Aβ
in different ways leading to differential co-aggregation of
Aβ in parenchymal plaque versus CAA. In addition, we
found that 5XFAD/apoEm/4 have an intermediate level of
CAA as compared to either 5XFAD/apoEm/m or 5XFAD/
apoE4/4 mice. This is important as it is consistent with hu-
man data in which it has been found that apoE4, in a
dose-dependent fashion, is associated with greater paren-
chymal CAA [22, 30, 42].
To investigate the co-aggregation of different apoE in
plaques and CAA, we assessed co-localization of apoE
and amyloid in these two lesions in the same brain. Our
data clearly demonstrated that within the brain paren-
chyma, the degree to which apoE co-localizes with Aβ in
plaques or CAA was associated with its ability to facilitate
the corresponding lesion. Aβ plaques contained more
mouse apoE which facilitates plaque deposition (Fig. 2b),
while parenchymal CAA contained more apoE4 which fa-
cilitates the formation of parenchymal CAA (Fig. 2d). In
Fig. 5 ApoE levels in 85-day-old apoEm/4 and APPPS1-21/apoEm/4 brains. The cortices were homogenized in PBS, followed by 1 % Triton X-100
and 5 M guanidine and apoE levels were measured by ELISA. a-b Absolute concentrations and fractional distribution of mouse apoE and apoE4
in apoEm/4 mice (n = 10). c-d Absolute concentrations and fractional distribution of mouse apoE and apoE4 in APPPS1-21/apoEm/4 mice (n = 10;
*p < 0.05; **p < 0.01; ***p < 0.001, Two-way ANOVA for repeated measures followed by Bonferroni post-test). e-g Correlations of Aβ42 with mouse apoE,
apoE4 and Aβ40 in the insoluble fraction of APPPS1-21/apoEm/4 cortices (n = 10)
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addition, the fact that parenchymal plaques contained
more apoE (regardless of whether it is mouse apoE or
apoE4) also suggested that apoE interacted with Aβ in pla-
ques and CAA differently.
While most apoE present in physiological fluids such
as CSF may not complex with monomeric Aβ [36], there
is no question that once Aβ aggregates in the brain paren-
chyma or in CAA in the form of fibrils, apoE is then found
co-aggregated with amyloid. However, data quantifying
the amount of individual apoE isoforms co-depositing
with Aβ in plaques or CAA are lacking. Although in
PDAPP/apoE4/4 mice, the co-localization of apoE with
Aβ plaques was higher than that in PDAPP/apoE3/3 and
PDAPP/apoE2/2 mice [1], the different Aβ concentration
and oligomerization states in individual mice with different
apoE genotypes could influence the results. In the current
study, the co-localization of different forms of apoE with
different amyloid lesions within brain parenchyma was
compared in the same mice carrying one copy of each
apoE isoform and expressing each copy under the same
regulatory elements at the same level (5XFAD/apoEm/4).
Thus, the Aβ environment was identical for both apoE
isoforms and the data provided definitive in vivo confirm-
ation that mouse apoE and human apoE4 differentially fa-
cilitate specific types of amyloid deposition at least in part
by co-aggregating with them differentially. The different %
area covered by mouse apoE vs. human apoE4 observed
here is likely not an artifact caused by the performance
of apoE antibodies since plaques co-localized more with
mouse apoE while parenchymal CAA co-localized more
with apoE4. Furthermore, this co-localization of apoE
and Aβ in plaques was verified by correlating Aβ with
different apoE in the insoluble fraction of APPPS1-21/
apoEm/4 mice. Interestingly, while our current data and
previous studies using APP transgenic mice generating
normal human Aβ [10, 24] suggested that apoE4 redis-
tributed Aβ deposition to CAA as compared to mouse
apoE, a previous study using mice expressing human
Dutch/Iowa (E22Q/D23N) mutant Aβ showed an opposite
pattern [38]. In transgenic mice (Tg-SwDI) that accumulate
human Dutch/Iowa (E22Q/D23N) mutant Aβ, both hu-
man apoE3 and apoE4 strongly shifted the Aβ deposition
from CAA into plaques [38]. Unlike in general AD popula-
tions where apoE4 is strongly associated with increased
plaques and CAA, in humans with the rare Dutch muta-
tion, apoE4 genotype was not correlated with plaques or
CAA [5]. The Dutch mutation resides within amino acids
12-28 of Aβ peptide, a domain which appears to be re-
quired for interaction with apoE [33]. Taken together, our
data and previous studies suggested that apoE modifies Aβ
pathology through interaction with Aβ aggregates.
Since mouse apoE and apoE4 in 5XFAD/apoEm/4 brains
were exposed to identical Aβ conditions, the co-aggregation
of different apoE with Aβ in plaques or CAA was
determined by the intrinsic properties of different apoE
such as their binding preference to a certain species of Aβ
or their concentration. CAA contains a higher Aβ40/Aβ42
ratio than do plaques [14] although Aβ42 is required to
“seed” CAA [19]. The observation that apoE4 better co-
localized with parenchymal CAA than plaques was not
likely due to its higher binding preference to Aβ40 over
Aβ42. If this were the case, we should expect to see even
more apoE4 present than mouse apoE in the leptomenin-
geal CAA since the ratio of Aβ40/Aβ42 is even higher in
leptomeningeal CAA than that in parenchymal CAA [26].
However in leptomeningeal CAA, we observed less apoE4
than mouse apoE. To see whether apoE levels play a role
in the different co-aggregation, we measured apoE levels in
cortical lysates of apoEm/4 and APPPS1-21/apoEm/4
mice. The total levels of mouse apoE and apoE4 in
brain lysates were similar (Fig. 5) in apoEm/4 mice but
their fractional distribution was different. In general there
was more mouse apoE in the PBS soluble fraction while
there was more human apoE4 in the insoluble fraction in
the non-APP/apoEm/4 mice. This suggests an inherent dif-
ference in the biochemical properties of mouse apoE vs.
human apoE4. It is possible that the conformation of
mouse apoE in the PBS soluble fraction localized in paren-
chyma in such a way to interact with Aβ seeds that forms
plaques as compared to apoE4 resulting in its precipita-
tion into plaques to a greater extent. It is also possible that
the structure of apoE4 may result in its localization to a
greater extent in the vasculature, enabling it to interact to
a greater extent with Aβ seeds that form CAA.
When leptomeningeal CAA and parenchymal CAA were
compared, we found that 1) leptomeningeal CAA con-
tained much higher apoE than did parenchymal CAA, and
2) leptomeningeal CAA contained more mouse apoE while
parenchymal CAA contained more apoE4. These observa-
tions suggested that apoE might be differently involved
during the formation of CAA in blood vessels of different
locations.
Conclusion
Understanding how apoE influences the development of
parenchymal plaques versus CAA is important. While
this study does not provide the molecular basis for why
mouse apoE and human apoE4 result in differential pla-
ques versus CAA, it demonstrates that apoE is a major
determinant of where Aβ deposits given that the Aβ in
the in vivo microenvironment is the same. Therefore,
studying the differences in sequence (30 % difference in
sequence) and structure between mouse and human apoE
that result in these differences could provide important in-
sights. For example, understanding the structural variations
could provide new insight into how to block or influence
the apoE/Aβ interaction. In addition, treatment with some
anti-Aβ antibodies has resulted in humans in the
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complication of amyloid-related imaging abnormalities ei-
ther with edema or hemorrhage. This complication is
far more frequent in apoE4 positive individuals [31, 32].
It was also observed that Aβ immunotherapy was asso-
ciated with redistribution of apoE from cortical plaques to
cerebral vessel walls, mirroring the altered distribution of
Aβ [28]. Understanding the basis for the differential effects
of apoE on plaques vs. CAA might provide important in-
sights into this phenomenon that could lead to ways to
understand and prevent it.
Additional files
Additional file 1: Figure S1. Aβ plaque onset age in 5XFAD/apoEm/m
and 5XFAD/apoE4/4 brain. Aβ immunostaining was performed using
biotinylated anti-Aβ1–13 monoclonal antibody HJ3.4B. a Brain section from
4 month old 5XFAD/apoEm/m mouse. b Brain section from 4 month old
5XFAD/apoE4/4 mouse. c Brain section from 5 month old 5XFAD/apoE4/4
mouse. Scale bar, 1 mm. Plaques are indicated by arrows. (TIF 2146 kb)
Additional file 2: Figure S2. Specific antibodies for mouse apoE and
human apoE4 immunostaining. 5XFAD/apoEm/m and 5XFAD/apoE4/4
brain sections were immunostained with HJ6.3B for mouse apoE and
HJ15.7B for human apoE4 (scale bar, 400 μm). (TIF 1678 kb)
Additional file 3: Figure S3. The ratio of mouse apoE to human apoE4
within different amyloid lesions in 10 month old 5XFAD/apoEm/4 brains
shown in Fig. 2 and Fig. 3 (n = 8/group; ***, p < 0.001; One-way ANOVA
repeated measures). (TIF 174 kb)
Additional file 4: Figure S4. Specific ELISA for mouse apoE and human
apoE. a Mouse apoE was detected by using HJ6.2 as the capture antibody
and HJ6.8-biotin as the detecting antibody. b Human apoE was detected
using HJ15.6 as the capture antibody and HJ15.4-biotin as the detecting
antibody. (TIF 372 kb)
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